Eugastro GmbH
- Address
- lock Available on a paid plan
Digestive System Diseases and Inflammatory Bowel Disease
At Eugastro GmbH in Leipzig, a major share of research focuses on digestive system diseases, especially Crohn’s disease and ulcerative colitis. These studies are designed to evaluate new treatments, compare active therapies, and better understand long-term control of intestinal inflammation.
- Clinical research in Crohn’s disease and ulcerative colitis
- Studies assessing treatment effectiveness and safety in inflammatory bowel disease
- Work on improving maintenance therapy and symptom control
Several trials also address related conditions such as irritable bowel syndrome, supporting a broad gastrointestinal research program at the site.
Liver Disease, Metabolic Disorders, and Nutritional Health
Another important research area covers liver diseases linked to metabolic dysfunction, including NASH, MASH, cirrhosis, and alcohol-related liver disease. These trials aim to test new therapies, slow disease progression, and improve liver function and clinical outcomes.
- Studies in non-alcoholic steatohepatitis and metabolic dysfunction-associated steatotic liver disease
- Research in cirrhosis and advanced liver complications
- Trials evaluating medicines for obesity and related metabolic risk
The site’s work in this field reflects strong interest in the connection between metabolism, weight-related disease, and progressive liver injury.
Virus Diseases and Chronic Hepatitis
Clinical trials at Eugastro GmbH also include research on virus diseases, particularly chronic hepatitis C and chronic hepatitis B. These studies are focused on evaluating antiviral treatment effectiveness and helping patients achieve better long-term disease control.
- Trials in chronic hepatitis C virus infection
- Research in chronic viral hepatitis B
- Studies testing therapies aimed at improving viral suppression and liver health
This area highlights the site’s role in advancing care for persistent liver infections that can lead to serious complications over time.
Immune System Diseases and Autoimmune Liver Conditions
Research at the site includes immune system diseases with a strong emphasis on autoimmune and cholestatic liver disorders such as primary biliary cholangitis. These trials are intended to evaluate new treatment options and improve disease management for patients with chronic immune-mediated conditions.
- Studies in primary biliary cholangitis
- Research on immune-driven liver inflammation and cholestasis
- Trials exploring better treatment response and symptom reduction
The work broadens the site’s expertise beyond gastrointestinal care into immune-related disease research with important liver-focused applications.
Motility, Upper GI, and Nutritional Disorders
Additional trials at Eugastro GmbH cover a range of upper gastrointestinal and nutritional/metabolic conditions, including gastroparesis, erosive esophagitis, short bowel syndrome, and hereditary hemochromatosis. The aim is to test new ways to improve digestion, healing, nutrient handling, and overall quality of life.
- Studies in gastroparesis and delayed stomach emptying
- Research on erosive esophagitis and reflux-related disease
- Trials in short bowel syndrome, obesity, and iron metabolism disorders
These projects show a broad clinical portfolio that links digestive health with metabolic regulation and nutrient absorption.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 5 therapeutic areas and 15 of 42 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 42 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 11 by active trials.
- 1Janssen Cilag International4active
lock +10 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International8trials
lock +8 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Eugastro GmbH
lock Showing 1 of 44 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2, Double-Blinded, Randomized, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy and Safety of GS-5290 in Participants With Moderately to Severely Active Ulcerative Colitis | Gilead Sciences Inc. | Phase II | Recruiting | Apr 2024 | — |
IMP list
lock Showing 1 of 42 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Guselkumab | 5 | Unknown | 2018-07-26 | 2022-11-30 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.